Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph J Carreno

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Infectious Diseases and Therapy|September 7, 2014
Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTUREJoseph J Carreno, Thomas P Lodise
Pharmacotherapy|September 16, 2014
Vancomycin-associated renal dysfunction: where are we now?Joseph J Carreno, Rachel M Kenney, Ben Lomaestro
American Journal of Infection Control|March 19, 2015
Shifting trends in the incidence of Pseudomonas aeruginosa septicemia in hospitalized adults in the United States from 1996-2010Brian J Werth, Joseph J Carreno, Kelly R Reveles
American Journal of Infection Control|February 3, 2023
Population based cohort to examine association between geospatial antibiotic factors and urinary tract infection outcomesAlexa Nero, Mckayla Weber, Kelly R Reveles, et al.
Antimicrobial Agents and Chemotherapy|March 15, 2017
Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic SamplingJoseph J Carreno, Ben Lomaestro, John Tietjan, et al.
Infectious Diseases and Therapy|August 20, 2014
Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving VancomycinJoseph J Carreno, Anthony Jaworski, Rachel M Kenney, et al.
Pharmacotherapy|October 24, 2021
Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases PharmacistsNimish Patel, Jeannette Bouchard, Meredith B Oliver, et al.
The Annals of Pharmacotherapy|November 14, 2016
Randomized Controlled Trial to Determine the Efficacy of Early Switch From Vancomycin to Vancomycin Alternatives as a Strategy to Prevent Nephrotoxicity in Patients With Multiple Risk Factors for Adverse Renal Outcomes (STOP-NT)Joseph J Carreno, Rachel M Kenney, George Divine, et al.
Open Forum Infectious Diseases|January 26, 2022
Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream InfectionsThomas P Lodise, Marc Scheetz, Joseph J Carreno, et al.
Open Forum Infectious Diseases|January 29, 2020
Antibiotic Prescribing in New York State Medicare Part B Beneficiaries Diagnosed With Cystitis Between 2016 and 2017Joyce Y Yu, Valerie A McKenna, Ghinwa K Dumyati, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Infectious Diseases and Therapy|September 7, 2014
Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTUREJoseph J Carreno, Thomas P Lodise
Pharmacotherapy|September 16, 2014
Vancomycin-associated renal dysfunction: where are we now?Joseph J Carreno, Rachel M Kenney, Ben Lomaestro
American Journal of Infection Control|March 19, 2015
Shifting trends in the incidence of Pseudomonas aeruginosa septicemia in hospitalized adults in the United States from 1996-2010Brian J Werth, Joseph J Carreno, Kelly R Reveles
American Journal of Infection Control|February 3, 2023
Population based cohort to examine association between geospatial antibiotic factors and urinary tract infection outcomesAlexa Nero, Mckayla Weber, Kelly R Reveles, et al.
Antimicrobial Agents and Chemotherapy|March 15, 2017
Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic SamplingJoseph J Carreno, Ben Lomaestro, John Tietjan, et al.
Infectious Diseases and Therapy|August 20, 2014
Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving VancomycinJoseph J Carreno, Anthony Jaworski, Rachel M Kenney, et al.
Pharmacotherapy|October 24, 2021
Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases PharmacistsNimish Patel, Jeannette Bouchard, Meredith B Oliver, et al.
The Annals of Pharmacotherapy|November 14, 2016
Randomized Controlled Trial to Determine the Efficacy of Early Switch From Vancomycin to Vancomycin Alternatives as a Strategy to Prevent Nephrotoxicity in Patients With Multiple Risk Factors for Adverse Renal Outcomes (STOP-NT)Joseph J Carreno, Rachel M Kenney, George Divine, et al.
Open Forum Infectious Diseases|January 26, 2022
Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream InfectionsThomas P Lodise, Marc Scheetz, Joseph J Carreno, et al.
Open Forum Infectious Diseases|January 29, 2020
Antibiotic Prescribing in New York State Medicare Part B Beneficiaries Diagnosed With Cystitis Between 2016 and 2017Joyce Y Yu, Valerie A McKenna, Ghinwa K Dumyati, et al.
Pageof 3